MYCN’s expression levels without some or all of the listed mutations of MYCN and ALK were derived from an experimental study [90].vThe wild-type MAPK/RAS pathway’s signalling activity was derived from
Minichromosome maintenance complex component 6 (MCM6), as an important replication permission factor, is involved in the pathogenesis of various tumors. we studied the expression of MCM6 in neuroblast
ALK mutations occur in 10% of primary neuroblastoma and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype with
There is increasing evidence that soluble factors in inflammatory central nervous system diseases not only regulate the inflammatory process but also directly influence electrophysiological membrane p
